Sex-related differences in outcomes among men and women under 55 years of age with acute coronary syndrome undergoing percutaneous coronary intervention: Results from the PROMETHEUS study

Catheterization and Cardiovascular Interventions

Volumn 89, Issue 4, 2017, Pages 629-637

  Chandrasekhar, Jaya ^a   Baber, Usman ^a   Sartori, Samantha ^a   Faggioni, Michela ^a   Aquino, Melissa ^a   Kini, Annapoorna ^b   Weintraub, William ^c   Rao, Sunil ^d   Kapadia, Samir ^e   Weiss, Sandra ^c   Strauss, Craig ^f   Toma, Catalin ^g   Muhlestein, Brent ^h   DeFranco, Anthony ⁱ   Effron, Mark ^j,k   Keller, Stuart ^k   Baker, Brian ^l   Pocock, Stuart ^m   Henry, Timothy ⁿ   Mehran, Roxana ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI HOSPITAL   (United States)

^c CHRISTIANA CARE HEALTH SYSTEM   (United States)

^d DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e LERNER RESEARCH INSTITUTE   (United States)

^f MINNEAPOLIS HEART INSTITUTE FOUNDATION   (United States)

^g UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^h Intermountain Heart Institute   (United States)

ⁱ Aurora Cardiovascular Services   (United States)

^j OCHSNER MEDICAL CENTER   (United States)

^k ELI LILLY AND COMPANY   (United States)

^l DAIICHI SANKYO INC   (United States)

^m LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

ⁿ CEDARS SINAI MEDICAL CENTER   (United States)

more..

Author keywords

long term outcomes; percutaneous coronary intervention; sex related differences; under treatment in women; young patients with acute coronary syndrome

Indexed keywords

ACETYLSALICYLIC ACID; BIVALIRUDIN; CLOPIDOGREL; FIBRINOGEN RECEPTOR ANTAGONIST; PRASUGREL; ANTITHROMBOCYTIC AGENT; TICLOPIDINE;

ACUTE CORONARY SYNDROME; ADULT; ARTICLE; BLEEDING; BLOOD TRANSFUSION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; CHRONIC KIDNEY FAILURE; COHORT ANALYSIS; DIABETES MELLITUS; DUAL ANTIPLATELET THERAPY; ETHNIC DIFFERENCE; FEMALE; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; PREVALENCE; PROPORTIONAL HAZARDS MODEL; PROSPECTIVE STUDY; RETROSPECTIVE STUDY; RISK ASSESSMENT; SEX DIFFERENCE; TREATMENT OUTCOME; ADVERSE EFFECTS; AGE; ANALOGS AND DERIVATIVES; CLINICAL TRIAL; COMBINATION DRUG THERAPY; FOLLOW UP; INCIDENCE; MIDDLE AGED; POSTOPERATIVE COMPLICATIONS; PROGNOSIS; SEX RATIO; SURVIVAL RATE; TRENDS; UNITED STATES;

ACUTE CORONARY SYNDROME; AGE FACTORS; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HUMANS; INCIDENCE; MALE; MIDDLE AGED; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS; POSTOPERATIVE COMPLICATIONS; PRASUGREL HYDROCHLORIDE; PROGNOSIS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; SEX DISTRIBUTION; SEX FACTORS; SURVIVAL RATE; TICLOPIDINE; TREATMENT OUTCOME; UNITED STATES;

EID: 84971467421     PISSN: 15221946     EISSN: 1522726X     Source Type: Journal    
DOI: 10.1002/ccd.26606     Document Type: Article

References (22)

1. Vaccarino V, Horwitz RI, Meehan TP, et al. Sex differences in mortality after myocardial infarction: Evidence for a sex-age interaction. Arch Intern Med 1998;158:2054–2062.
2. Champney KP, Frederick PD, Bueno H, et al. The joint contribution of sex, age and type of myocardial infarction on hospital mortality following acute myocardial infarction. Heart 2009;95:895–899.
3. Yu J, Mehran R, Grinfeld L, et al. Sex-based differences in bleeding and long term adverse events after percutaneous coronary intervention for acute myocardial infarction: Three year results from the HORIZONS-AMI trial. Catheter Cardiovasc Interv 2015;85:359–368.
4. Baber U, Sartori S, Aquino M, Strauss C, Muhlestein JB, Rao S, Kini A, Toma C, Poddar KL, Kapadia S, Weintraub W, Chandrasekhar J, Weiss S, DeFranco A, Baker B, Marrett E, Molife C, Faries D, Keller S, Effron M, Pocock S, Mehran R. 90-Day effectiveness and safety of prasugrel vs. clopidogrel as used in clinical practice in patients with ACS undergoing PCI: Initial findings from the PROMETHEUS study. In: SCAI Late Breaking Clinical Trial presentation, San Diego, 2015.
5. Dangas GD, Claessen BE, Mehran R, et al. Development and validation of a stent thrombosis risk score in patients with acute coronary syndromes. JACC Cardiovasc Interv 2012;5:1097–1105.
6. Peterson ED, Dai D, DeLong ER, et al. Contemporary mortality risk prediction for percutaneous coronary intervention: Results from 588,398 procedures in the National Cardiovascular Data Registry. J Am Coll Cardiol 2010;55:1923–1932.
7. Suh J, Park DW, Lee JY, et al. The relationship and threshold of stent length with regard to risk of stent thrombosis after drug-eluting stent implantation. JACC Cardiovasc Interv 2010;3:383–389.
8. Rao SV, McCoy LA, Spertus JA, et al. An updated bleeding model to predict the risk of post-procedure bleeding among patients undergoing percutaneous coronary intervention: A report using an expanded bleeding definition from the National Cardiovascular Data Registry CathPCI Registry. JACC Cardiovasc Interv 2013;6:897–904.
9. Mehran R, Pocock S, Nikolsky E, et al. Impact of bleeding on mortality after percutaneous coronary intervention results from a patient-level pooled analysis of the REPLACE-2 (randomized evaluation of PCI linking angiomax to reduced clinical events), ACUITY (acute catheterization and urgent intervention triage strategy), and HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trials. JACC Cardiovasc Interv 2011;4:654–664.
10. Baber U, Mehran R, Giustino G, et al. Coronary thrombosis and major bleeding after PCI with drug-eluting stents: Risk scores from PARIS. J Am Coll Cardiol 2016;67:2224–2234.
11. Maas AH, Appelman YE. Gender differences in coronary heart disease. Neth Heart J 2010;18:598–602.
12. Maas AH, van der Schouw YT, Regitz-Zagrosek V, et al. Red alert for women's heart: The urgent need for more research and knowledge on cardiovascular disease in women: Proceedings of the workshop held in Brussels on gender differences in cardiovascular disease, 29 September 2010. Eur Heart J 2011;32:1362–1368.
13. Ruiz-Garcia J, Lerman A, Weisz G, et al. Age- and gender-related changes in plaque composition in patients with acute coronary syndrome: The PROSPECT study. EuroIntervention 2012;8:929–938.
14. Hess CN, McCoy LA, Duggirala HJ, et al. Sex-based differences in outcomes after percutaneous coronary intervention for acute myocardial infarction: A report from TRANSLATE-ACS. J Am Heart Assoc 2014;3:e000523.
15. Lansky AJ, Ng VG, Maehara A, et al. Gender and the extent of coronary atherosclerosis, plaque composition, and clinical outcomes in acute coronary syndromes. JACC Cardiovasc Imaging 2012;5:S62–S72.
16. Qian J, Maehara A, Mintz GS, et al. Impact of gender and age on in vivo virtual histology-intravascular ultrasound imaging plaque characterization (from the global Virtual Histology Intravascular Ultrasound [VH-IVUS] registry). Am J Cardiol 2009;103:1210–1214.
17. Pundziute G, Schuijf JD, van Velzen JE, et al. Assessment with multi-slice computed tomography and gray-scale and virtual histology intravascular ultrasound of gender-specific differences in extent and composition of coronary atherosclerotic plaques in relation to age. Am J Cardiol 2010;105:480–486.
18. Wiviott SD, Braunwald E, McCabe CH, et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007;357:2001–2015.
19. Wiviott SD, Trenk D, Frelinger AL, et al. Prasugrel compared with high loading- and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: The prasugrel in comparison to clopidogrel for inhibition of platelet activation and aggregation-thrombolysis in myocardial infarction 44 trial. Circulation 2007;116:2923–2932.
20. Robson R. The use of bivalirudin in patients with renal impairment. J Invasive Cardiol 2000;12(Suppl F):33F–36F.
21. Mehilli J, Neumann FJ, Ndrepepa G, et al. Sex-related effectiveness of bivalirudin versus abciximab and heparin in non-ST-segment elevation myocardial infarction. Am Heart J 2013;165:537–543.
22. Yu J, Mehran R, Clayton T, et al. Prediction of 1-year mortality and impact of bivalirudin therapy according to level of baseline risk: A patient-level pooled analysis from three randomized trials. Catheter Cardiovasc Interv 2016;87:391–400.